To include your compound in the COVID-19 Resource Center, submit it here.

Vertex reports Phase II data for pain candidate VX-150

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) reported data from a Phase II trial in 243 patients with acute pain following bunionectomy showing that

Read the full 216 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE